Drugs / NEZUTATUG
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05919537 | Sep 2023 → Mar 2031 expected | malignant pancreatic neoplasm, metastatic neoplasm, non-small cell lung carcinoma | Hummingbird Bioscience | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05910827 | Feb 2024 → Dec 2027 expected | cervical squamous cell carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, nasopharyngeal carcinoma +2 | Hummingbird Bioscience | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05057013 | Nov 2021 → Nov 2025 overdue | castration-resistant prostate carcinoma, cervical cancer, colorectal cancer, endometrial cancer +10 | Cancer Research UK | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2024-03-06 | Hummingbird Bioscience | Results Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024 hummingbirdbioscience.com ↗
The poster will highlight that more than 80% tumor growth inhibition is seen across multiple preclinical models with common HER3 mutations. |
| 2023-10-23 | Hummingbird Bioscience | Results Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023 hummingbirdbioscience.com ↗
Disease control rate (DCR) was 43% (9/21), with one patient achieving partial response with a 51% tumor shrinkage after four cycles of HMBD-001 treatment. |
| 2023-03-15 | Hummingbird Bioscience | Results Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023 hummingbirdbioscience.com ↗
Robust tumor growth inhibition in various preclinical squamous cancer models, including lung, esophageal and head and neck, is observed with HMBD-001 when used as monotherapy and in combination with cetuximab. |
| 2021-10-07 | Hummingbird Bioscience | Results Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-Driven Cancers hummingbirdbioscience.com ↗
In pre-clinical models that carried these biomarkers, Hummingbird’s differentiated and highly potent anti-HER3 antibody, HMBD-001, showed potent activity compared to previous generations of anti-HER3 antibodies. |
| 2021-08-02 | Hummingbird Bioscience | Regulatory Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers hummingbirdbioscience.com ↗ |
| 2018-11-09 | Hummingbird Bioscience | Results Hummingbird Bioscience to present poster data on HMBD-001-10D1 at the EORTC-NCI-AACR’s 30th Annual Meeting hummingbirdbioscience.com ↗
HMBD-001-10D1 has also been engineered to induce increased Antibody Dependent Cell mediated Cytotoxicity and demonstrates superior tumor growth inhibition in in vitro and in vivo models compared to existing anti-HER3 antibodies. |
All press releases naming this drug 13 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEZUTATUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315023 ↗ |
| Known as | HMBD-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05919537 ↗ |
| Modality | Monoclonal antibody | “HMBD-001 is a type of drug called a monoclonal antibody.” NCT05057013 ↗ |
| Route | Intravenous | “administered once a week as a 120-minute intravenous (IV) infusion.” NCT05057013 ↗ |